The American Heart Association updated the Coronary Artery Disease (CAD) guidelines for the first time in a decade. Join host, Geoff Wall, as he evaluates what's new in CAD pharmacotherapy.
 
The GameChanger
CAD pharmacotherapy is dependent on aggressive lipid management whereas antiplatelet and beta-blocker therapy is now more nuanced.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Reference
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Jul 20. doi: 10.1161/CIR.0000000000001168. Epub ahead of print. PMID: 37471501.

https://www.ahajournals.org/doi/epdf/10.1161/CIR.0000000000001168

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the new AHA coronary artery disease (CAD) guidelines
2. Apply AHA CAD guidelines for medical management of a patient with stable CAD

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-295-H01-P
Initial release date: 9/4/2023
Expiration date: 9/4/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram